logo
Plus   Neg
Share
Email

Acceleron Pharma's ACE-083 Fails In Phase 2 Study For FSHD

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

Although ACE-083 showed a significant increase in mean total muscle volume, which was the primary endpoint of the trial, the secondary endpoint of functional tests was failed. As a result, the company is not planning to continue with further study of ACE-083 for FSHD.

FSHD is a genetic muscle disorder that starts usually before the age of 20. It first affects the muscles of the face, shoulder blades and upper arms by weakening them, and gradually spreads to other muscles.

ACE-083 is also being explored as a potential treatment for Charcot-Marie-Tooth disease—a neuromuscular disorder, and a phase II trial in this indication is underway. Topline results from this trial are expected in the first quarter of the next year.

XLRN closed Monday's trading at $44.65, up 1.71%. In after-hours, the stock was down 6.83% to $41.60.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dunkin' Brands Group said it is rolling out the Beyond Sausage Sandwich to more than 9,000 restaurants nationwide, starting November 6. The sandwich features a plant-based sausage patty from alternative meat maker Beyond Meat. Beyond Meat's breakfast sausage patty is made with plant-based protein and a mix of spices crafted specifically for Dunkin'. Boeing said it understands and regrets the concern caused by the publications of instant messages involving a former test pilot that he "unknowingly" lied to regulators about a flight-control system on the Boeing 737 Max aircraft. The aircraft maker said it especially regrets the difficulties that the release of the messages presented for the U.S. Federal Aviation Administration or FAA. Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people.
RELATED NEWS
Follow RTT
>